Competing Interests: The authors have declare that no competing interests exist.
Patients with systemic lupus erythematosus are at increased risk for alveolar bone loss due to periodontitis possibly as a result of a pathogenic immune response to oral bacteria and inflammation. The aim of the present study was to investigate whether an anti-TNF-α antagonist could prevent mandibular bone loss in the FcγRIIb-/- mouse model of lupus. Mice lacking FcγRIIb had decreased cancellous and cortical bone volume at 6 months of age. Etanercept increased cancellous but not cortical bone volume in WT and increased both cancellous bone volume and cortical thickness in FcγRIIb-deficient mice. FcγRIIb deficiency decreased mRNA levels for osteoblast marker genes, Osx, Col1a1 and Alp without any change in osteoclast marker genes. Etanercept increased Osx, Alp, and Ocn in both WT and FcγRIIb-/- mice. Osteoclast marker genes including TNF-α, Trap and RANKL/OPG ratio was decreased in WT. Serum markers of proinflammatory cytokines, TNF-α, IFNγ, IL-6, and IL-17A, were increased in FcγRIIb-/- mice and etanercept antagonized these effects in FcγRIIb-/- mice. Etanercept increased serum PTH levels in the FcγRIIb-/- mouse model of lupus. Our results suggest that deletion of FcγRIIb induces osteopenia by increasing the level of proinflammatory cytokines. Etanercept is effective in preventing mandibular bone loss in FcγRIIb-/- mice, suggesting that anti-TNF-α therapy may be able to ameliorate mandibular bone loss in SLE patients with periodontitis.
Periodontitis is a chronic inflammation and destruction of periodontal tissue leading to mandibular alveolar bone loss induced by osteoclasts. Gram-negative bacteria, including Porphyromonas gingivalis and Aggregatibacter actinomycetemcomitans were identified as major periodontal pathogens [1]. They produce virulence factors that disturb host-microbe homeostasis. In addition to the microbial challenge, the progression of periodontitis is caused by local inflammation and over activation of the host immune response which stimulates osteoclast activity leading to alveolar bone loss [2]. Myeloid cells including monocytes and macrophages may be responsible for collateral damage to the periodontal tissues. Phagocytosis of pathogenic microorganisms by myeloid cell populations leads to the penetration of bacteria into periodontal tissue [3].
Immunoglobulin Fc receptors (FcRs) are expressed on a wide range of cells and mediate recognition of the Fc region of immunoglobulin. Fc gamma receptor (FcγR) play crucial roles in antibody-mediated immune responses. Four classes of FcγR, FcγRI, FcγRII, FcγRIII and FcγRIV have been identified in mammals [4]. Binding of immune complexes to FcγR results in phagocytosis of IgG-opsonized particles, antibody-dependent cellular cytotoxicity, and release of inflammatory mediators. During periodontal infection, polymorphonuclear neutrophilic leukocytes (PMN) expressing FcγRIIa are involved in periodontal tissue degradation by releasing reactive oxygen species and proteases. It has been shown that periodontitis patients with FcγRIIa-131H/H genotype have hyper-reactivity in response to stimulation with pathogenic bacteria leading to more severe periodontal breakdown and bone loss than the patients with FcγRIIa‐131H/R or 131R/R genotype [5].
A potential correlation between periodontal and autoimmune diseases, including systemic lupus erythematosus (SLE) has been shown. Approximately 93.8% of SLE patients had periodontitis [6]. SLE is a chronic autoimmune disease characterized by the loss of B and T cell tolerance to self-antigens, resulting in inflammation in various part of the body. SLE patients are at increased risk for periodontitis possibly as a result of a pathogenic immune response to oral bacteria and inflammation. The pathogenesis of abnormal inflammation in SLE is not completely understood. FcγRIIb, a negative regulator of B cell receptor signaling, is associated with SLE. Mice deficient in FcγRIIb exhibit SLE and its partial restoration rescues the disease [7, 8]. FcγRIIb deficiency leads to decreased disposal of immune complexes, the breakdown of self-tolerance and inability to modulate inflammatory response. FcγRIIb-deficient H-2b mice are prone to collagen-induced arthritis [9]. Destructive cartilage and focal eroded bone surface are found in histological examination of arthritic paws.
Using anti-dsDNA antibody, a marker of SLE, our previous study indicated that mice deficient in FcγRIIb developed spontaneous SLE at 6 months of age. It has been reported that SLE patients have multiple B cell abnormalities, including an increase in the number of circulating plasma cells [10]. These patients produce a variety of autoantibodies directed against nuclear, cytoplasmic and cell surface autoantigens. The SLE disease activity correlates with the frequency of circulating plasma cells [11]. Our flow cytometry confirmed that B220lowCD138+ plasma cells, were increased in 6 but not 3 months old FcγRIIb -/- mice [12]. FcγRIIb-/- mice were osteopenic in both cortical bone and cancellous bone in tibiae. Cortical bone area and mechanical properties were reduced at 6 months of age. Deletion of FcγRIIb induced cancellous bone loss in tibiae due to increased bone resorption without any change in bone formation. FcγRIIb-deficient mice displayed increased serum levels of the proinflammatory cytokine, tumor necrosis factor-alpha (TNF-α). Therefore, deletion of FcγRIIb increased TNF-α-mediated bone resorption leading to inflammatory bone loss. However, the mechanisms by which absence of FcγRIIb affects mandibular bone turnover during inflammation have not been elucidated. Patients with periodontitis have higher serum and saliva levels of TNF-α than healthy individuals [13]. FcγRIIa and FcγRIIb polymorphism are associated with SLE and periodontitis. SLE patients who have the combined FcγRIIa-R131 and FcγRIIb-232T alleles exhibit more severe tissue destruction compared to other SLE patients [14].
The present study aimed to investigate whether administration of an anti-TNF-α inhibitor could ameliorate mandibular bone loss in FcγRIIb-/- mice. Similar to observations in long bones, deletion of FcγRIIb induced mandibular bone loss in 6 months old mice. Etanercept (Enbrel), a soluble TNF p75 receptor that acts as a TNF-α antagonist by inhibiting TNF-α interaction with its cell surface receptor, significantly decreased systemic inflammation and bone loss in the FcγRIIb-/- lupus model. Anti-TNF-α increased serum PTH level only in FcγRIIb-/- mice. Our results suggested that absence of FcγRIIb induces inflammation and mandibular bone loss and that the anti-TNF-α antagonists ameliorate these effects.
FcγRIIb-/- mice were provided by Dr. Silvia Bolland (NIAID, NIH, Maryland, USA) and housed at the Faculty of Medicine, Chulalongkorn University. All animal procedures were approved by the Institutional Animal Care and Use Committee at Faculty of Medicine, Chulalongkorn University. Mice were maintained in accordance with the Guide for the Care and Use of Laboratory Animals (eighth edition), National Research Council. They had free access to water and standard rodent chow (C.P. Mice Feed, Perfect Companion Group Co., Ltd., Thailand)
Male and female heterozygous (FcγRIIb+/-) mice were crossed to generate FcγRIIb-/- mice and their WT littermates. FcγRIIb-/- and WT controls were genotyped by PCR from tail biopsies as described earlier [15]. Three- and 6-month-old FcγRIIb-/- males and WT controls were used to evaluate a skeletal phenotype. They were anesthetized with isoflurane and sacrificed by cervical dislocation. Left mandibles were fixed in 10% neutral buffered formalin for microcomputed tomography (μCT) analysis.
For etanercept studies, 6-month-old FcγRIIb-/- males and WT controls were subcutaneously injected with 16 doses of either PBS or 25 mg/kg etanercept (Enbrel, Wyeth, New Jersy, USA) which is an intermediate dose twice a week for 8 weeks [16]. At the end of the experiment, blood samples were collected, centrifuged at 10,000 rpm for 10 minutes and kept at −80°C for determination of serum proinflammatory cytokines and PTH levels. Left mandibles were fixed in 10% neutral buffered formalin for μCT analysis. Right mandibles were frozen in liquid nitrogen and kept at −80°C for RNA isolation and qPCR.
μCT was used to analyze cortical and cancellous bone microarchitecture using a desktop μCT35, (Scanco Medical, Basserdorf, Switzerland) in accordance with recommended guidelines [17]. Buccal-lingual cross slices of the first mandibular molars were scanned at 7 μm isotropic voxel size, 73 kVp, and 113 μA. Mandibular bone scans were subjected to Gaussian filtration and segmentation and the threshold was set at 33% of the maximal gray scale value. For cortical bone, cross-sectional volume (mm3), cortical volume (mm3), marrow volume (mm3), cortical thickness (mm), and bone mineral density (BMD, mgHA/cm2) were determined. Cancellous bone volume (BV/TV, %), trabecular thickness (Tb.Th, mm), trabecular number (Tb.N, /mm), trabecular separation (Tb.Sp, mm), structure model index (SMI), and bone mineral density (mgHA/cm2) were analyzed.
Total RNA was extracted from the right mandibles using Trizol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer’s procedure. RNA samples were further purified using an RNeasy Mini kit (Qiagen, Germantown, MD, USA) and the RNA yields were measured using a NanoDrop 1000 (Thermo Fisher Scientific, CA, USA). The cDNA was synthesized from 500 ng of total RNA with SuperScript VILO cDNA synthesis kit (Invitrogen, Carlsbad, CA, USA). The qPCR reaction was performed using the Luna Universal qPCR Master Mix (New England Biolabs) and was conducted at 60°C for 40 cycles using CFX96TM Optics Module (Bio-Rad, CA, USA). Gene expression profiles were normalized to GAPDH. The oligonucleotide primers for qPCR are shown in Supplementary S1 Table.
Mouse serum IL-23, IL1α, TNF-α, IFNγ, MCP-1, IL-12p70, IL-1β, IL-10, IL-6, IL-27, IL-17A, IFNβ, and GM-CSF levels were analyzed using a multiplex beads-based assay (LEGENDplexTM) according to the manufacturer’s instructions (BioLegend, San Diego, CA, USA). Serum PTH was measured using the mouse PTH (1–84) ELISA kit (Quidel, San Diego, CA) that detects the biologically active intact form of PTH.
All results are presented as mean ± SEM. Unpaired Student’s t-tests were used to compare two group means. Multiple comparisons were analyzed by one-way ANOVA followed by Fisher’s protected least significant difference test. Interactions between etanercept and FcγRIIb deficiency were analyzed by two-way ANOVA. Differences were considered statistically significant at p < 0.05.
Previous studies indicated that FcγRIIb-/- mice developed spontaneous SLE at 6 months of age. FcγRIIb-/- mice exhibited a normal skeletal phenotype at 3 months of age [12, 15]. To evaluate whether the absence of FcγRIIb affected mandibular cancellous and cortical bone in 3-month-old mice, μCT analysis was performed. μCT analysis showed no difference in cancellous bone volume, trabecular thickness, structure model index (SMI), and bone mineral density (BMD) (Fig 1A and 1B). Trabecular number (22.80±1.00 vs 23.38±0.44 /mm) and trabecular separation (0.074±0.001 vs 0.076±0.001 mm) did not change. Cross-sectional volume, cortical volume, and cortical thickness also did not change (Fig 1A and 1B). Marrow volume (0.028±0.002 vs 0.027±0.001 mm3) was not altered. These results indicated that FcγRIIb deletion did not affect mandibular bone turnover at 3 months of age prior to the development of the lupus phenotype.
Deletion of FcγRIIb induces cancellous and cortical bone loss in mandibles in 6- but not 3-month-old males.
(A) Representative μCT images of mandibular bone from 3- and 6-month-old FcγRIIb-/- mice and WT controls. (B) μCT analysis of cancellous and cortical bone in the mandibles from 3- and 6-month-old FcγRIIb-/- mice and WT controls. Data are mean ± SEM (n = 7–8). *p < 0.05 versus WT controls.
To further investigate whether FcγRIIb deletion resulted in mandibular abnormalities in mature adult mice with active SLE, we assessed the cancellous and cortical bone microarchitecture of the mandible in 6-month-old FcγRIIb-/- males. μCT analysis of the mandibles showed that FcγRIIb-/- mice were osteopenic with significantly decreased cancellous bone volume (11%), and trabecular thickness (10%) (Fig 1B) without any change in trabecular number (20.87±0.50 vs 21.50±0.34 /mm), trabecular separation (0.070±0.001 vs 0.073±0.001 mm), or connectivity density (81±15 vs 102±12 /mm3). SMI was increased by 72%. FcγRIIb-/- mice had lower cancellous BMD (7%) than WT littermate controls, indicating osteopenic phenotype. Cross-sectional volume, cortical volume (Fig 1B), and marrow volume (0.031±0.001 vs 0.025±0.002 mm3) were significantly reduced by 15, 14, and 19%, respectively. Cortical thickness was dramatically decreased by 13% (Fig 1B). These findings demonstrated that FcγRIIb-/- mice had mandibular cancellous and cortical bone loss at 6 months of age.
Previously we observed that deletion of FcγRIIb increased the circulating level of TNF-α at 6 months of age [12]. TNF-α is associated with systemic inflammation in rheumatoid arthritis, ankylosing spondylitis, and periodontitis. Etanercept treatment was used to evaluate whether TNF-α is a key mediator of mandibular bone loss and to test whether TNF-α blockade can reverse this phenotype in the FcγRIIb-/- lupus model. 6-month-old FcγRIIb-/- males were treated with etanercept for 8 weeks. Similar to 6-month-old FcγRIIb-/- mice, 8-month-old FcγRIIb-/- mice exhibited mandibular bone loss. FcγRIIb-/- mice had significantly decreased cancellous bone volume, and trabecular thickness (Fig 2A and 2B) without any change in trabecular number (22.20±0.58 vs 22.63±0.51 /mm) and trabecular separation (0.076±0.001 vs 0.072±0.002 mm). SMI was increased in FcγRIIb-/- mice, indicating a rod like structure. Deletion of FcγRIIb decreased cross-sectional volume, cortical volume, and cortical thickness (Fig 2A and 2B), whereas marrow volume did not change (0.027±0.002 vs 0.028±0.001 mm3). BMD was decreased in both cortical and cancellous bone (Fig 2B).
Mandibular cancellous and cortical bone loss are rescued by TNF-α inhibitor in FcγRIIb-/- mice.
(A) Representative μCT images of mandibular bone from FcγRIIb-/- mice and WT controls after treatment with either PBS or etanercept. (B) μCT analysis of cancellous and cortical bone in the mandibles from FcγRIIb-/- mice and WT controls after treatment with either PBS or etanercept. Data are mean ± SEM (n = 6–8). ap < 0.05 versus WT controls-treated with PBS, bp < 0.05 versus WT controls-treated with etanercept, and cp < 0.05 versus FcγRIIb-/- mice treated with PBS.
μCT analysis showed that TNF-α blockade with etanercept significantly increased cancellous bone volume by 5 and 17% in WT and FcγRIIb-/- mice, respectively (Fig 2B). Etanercept decreased trabecular separation (0.076±0.001 vs 0.070±0.001 mm) in WT. Trabecular thickness was increased whereas SMI were decreased, indicating plate like structure in FcγRIIb-/- mice treated with etanercept. Etanercept increased cross-sectional volume, cortical volume, and cortical thickness in FcγRIIb-/- mice (Fig 2B). Etanercept increased cancellous but not cortical bone mineral density only in FcγRIIb-/- mice. Two-way ANOVA indicated interaction between FcγRIIb deficiency and etanercept on cancellous bone volume, trabecular thickness, SMI, BMD, and cortical thickness. These findings proved that blockade of TNF-α by etanercept could prevent cancellous and cortical bone loss in the mandible.
To better understand the underlying mechanism by which etanercept prevented mandibular bone loss, osteoblast and osteoclast marker gene expression was evaluated. qPCR analysis showed a significant decrease in osteoblast-specific gene expression, including Osx, type I collagen α1 (Col1α1), and Alp, whereas Ocn, and FGF23 did not alter in FcγRIIb-/- mice treated with PBS (Fig 3A). There was no significant difference in a number of genes influencing osteoclastogenesis, including TNF-α, IFNγ, Nfatc1, and TGFβ (Fig 3B). Likewise, levels of osteoclast marker gene such as Trap, and RANKL/OPG were not significant altered. Interestingly, osteoblast-specific genes including Osx, Alp, and Ocn were significantly elevated in WT and FcγRIIb-/- mice treated with etanercept (Fig 3A). Etanercept increased Col1a1 expression only in FcγRIIb-/- mice but not WT. TNF-α, Trap, RANKL, and RANKL/OPG ratio were attenuated in WT-treated with etanercept (Fig 3B). However, IFNγ, Nfatc1, TGFβ mRNA levels were not altered. Deletion of FcγRIIb did not have any effect on genes related to osteoclastogenesis.
TNF-α blockade upregulates osteoblast marker gene expression in FcγRIIb-/- mice.
(A) qPCR analysis of osteoblast-specific genes. (B) qPCR analysis of osteoclast-specific genes. Data are mean ± SEM (n = 5–6). ap < 0.05 versus WT controls-treated with PBS, bp < 0.05 versus FcγRIIb-/- mice-treated with PBS, and cp < 0.05 versus WT controls treated with etanercept.
TNF-α induced inflammatory bone loss in long bone of FcγRIIb-/- mice [12]. To further investigate whether etanercept could diminish inflammatory-related mandibular bone loss, the circulating levels of proinflammatory cytokines including IL-23, IL-1α, TNF-α, IFNγ, MCP-1, IL-12p70, IL-1β, IL-10, IL-6, IL-27, IL-17A, IFNβ, GM-CSF were assessed. FcγRIIb-/- mice had elevated TNF-α, IFNγ, IL-6, IL-17A serum concentrations (Fig 4). Two-way ANOVA confirmed these effects. MCP-1 was slightly increased in FcγRIIb-/- mice with one-way ANOVA followed by Fisher’s protected least significant difference test (p = 0.094) however, two-way ANOVA indicated that deletion of FcγRIIb increased MCP-1. Our result confirmed our prior study that the circulating level of TNF-α was elevated following SLE development. IL-1α was decreased in WT-treated with etanercept but other cytokines were not altered (S2 Table). Etanercept slightly decreased serum TNF-α in FcγRIIb-/- mice (p = 0.09). Administration of etanercept significantly decreased serum IFNγ, IL-6 and IL-17A levels in FcγRIIb-/- mice. There was no effect on serum IL-23, IL-1α, IL-12p70, IL-1β, IL-10, IL-27, IFNβ, and GM-CSF levels after etanercept treatment (S2 Table). These data suggested that TNF-α inhibition prevented mandibular bone loss by decreasing circulating proinflammatory cytokines in FcγRIIb-/- mice.
Inflammatory cytokines are reduced by TNF-α antagonist.
Serum levels of TNF-α, IFNγ, IL-6, IL-17A, and MCP-1 in FcγRIIb-/- mice and WT controls after treatment with either PBS or etanercept. Data are mean ± SEM (n = 5–7). ap < 0.05 versus WT controls-treated with PBS, bp < 0.05 versus FcγRIIb-/- mice-treated with PBS, and cp < 0.05 versus WT controls treated with etanercept.
It has been shown that TNF inhibition increases serum PTH levels in patients with rheumatoid arthritis [18]. We determined whether etanercept would increase serum PTH levels in FcγRIIb-/- mice. Deletion of FcγRIIb did not have a significant effect on serum PTH level (77.11±15.82 vs 64.62±13.83 pg/ml). Interestingly, anti-TNF-α treatment increased serum level of PTH only in FcγRIIb-/- mice (64.62±13.83 vs 113.31±15.44 pg/ml, p<0.05) but not WT (77.11±15.82 vs 54.70±6.07 pg/ml). Two-way ANOVA indicated interaction between FcγRIIb deficiency and etanercept on serum PTH.
SLE is a chronic auto-immune inflammatory disease characterized by loss of self-tolerance with activation of autoreactive T and B cells resulting in hyperproduction of autoantibodies and damage to multiple organs. SLE patients are likely to suffer from periodontitis and SLE shares common pathogenic inflammatory characteristics with periodontitis. Oral manifestations of patients with SLE are common and typically include oral lesions coinciding with disease flares that lead to alveolar bone loss [19]. SLE patients have oral ulceration, honeycomb plaque, purpura, and petechiae in oral mucous membrane and periodontal tissue. TNF-α-induced inflammation may contribute to severe periodontitis leading to alveolar bone loss in SLE patients. We previously reported that absence of FcγRIIb resulted in spontaneous development of active SLE with overproduction of anti-dsDNA antibodies, increased splenic B220lowCD138+ plasma cells, and induced osteopenia in the long bones of male mice [12, 15]. However, there has been a lack of clinical data characterizing the effects of the inhibitory FcγR, FcγRIIb, on mandibular bone homeostasis in SLE patients with periodontitis.
The present study aimed to investigate whether TNF-α is a key mediator of mandibular bone loss in the FcγRIIb-/- model of lupus. Our data indicated that genetic deficiency of FcγRIIb induced mandibular bone loss in both cancellous and cortical bone sites by increasing proinflammatory cytokines and that TNF-α antagonist prevented proinflammatory cytokines-mediated mandibular bone loss in FcγRIIb-/- mice. Increases in cancellous and cortical bone volume were associated with increased bone formation and decreased bone resorption in WT-treated with etanercept. The expression of osteoblast marker genes, Osx, Alp and Ocn, were upregulated whereas osteoclast marker genes, TNF-α, Trap, RANKL/OPG ratio, were downregulated. However, etanercept increased Osx, Col1a1, Alp and Ocn without any alteration in osteoclast specific genes in FcγRIIb-/- mice. Deletion of FcγRIIb increased proinflammatory cytokines, including TNF-α, IFNγ, IL6, and IL-17A, and blocking TNF-α blunted these effects.
Genetic polymorphisms for FcγR, a member of immunoglobulin superfamily, were found in both SLE and periodontitis [14]. FcγRIIb-232T less effectively inhibited B cell receptor-mediated activation signal than FcγRIIb-232I, resulting in hyperactivation of B cells and increased risk for autoimmunity [20]. Kobayashi et al. demonstrated that both the stimulatory FcγRIIa-R131 and the inhibitory FcγRIIb-232T alleles were associated with SLE and periodontitis [14]. A combination of both FcγR risk alleles was associated with more severe periodontitis. FcγRI levels were upregulated whereas FcγRIIa and FcγRIIIb were downregulated in gingival crevicular fluid PMN [21]. The increased FcγRI expression by cytokines and bacterial stimuli concomitantly elevated IgA-mediated anti-P. gingivalis function, leading to clearance of P. gingivalis.
Both MRL/lpr and BXSB/MpJ-Yaa mice are well-established mouse models of SLE-related osteoporosis. A study by Schapira et al. reported that MRL/lpr mice with SLE-like phenotypes had decreased bone formation [22]. Transplantation of human bone marrow mesenchymal stem cells and stem cells from exfoliated deciduous teeth into MRL/lpr mice ameliorated severe bone loss by increasing osteoblastogenesis and decreasing osteoclastogenesis [23]. Three-month-old BXSB/MpJ-Yaa mice carrying a Y-linked autoimmune acceleration gene (Yaa) exhibited a normal bone homeostasis. However, osteopenia was observed at 6 months of age due to increased bone resorption with normal bone formation [24]. This study suggests that our finding of mandibular bone loss in FcγRIIb-/- lupus mice is likely broadly applicable to other SLE models.
In SLE patients, proinflammatory cytokines drive uncoupling of bone formation and bone resorption, resulting in osteopenia [25]. The underlying mechanisms of TNF-α-mediated bone loss in FcγRIIb deficiency were not fully understood. We observed that in FcγRIIb-/- mice elevations in serum TNF-α were associated with decreases in the expression of osteoblast-specific genes, including Osx, Col1a1, and Alp. This finding indicated that attenuations in mandibular cancellous and cortical bone volume were due to reduced bone formation in FcγRIIb-/- mice. The use of anti-TNF-α therapy in SLE is controversial. Anti-TNF-α drugs suppresses the local tissue damage, however the use of this drug is associated with the formation of autoantibodies, including antinuclear antibodies, antidouble-stranded DNA antibodies, and anticardiolipin antibodies [26]. As a consequence, TNF-α blockade could pose long-term danger in patients with lupus nephritis and symptoms can recur after cessation of anti-TNF-α therapy. TNF-α inhibitor treatment decreased staphylococcal enterotoxin-induced inflammatory arthritis, autoantibody formation and serum TNF-α production in MRL/lpr mice [27] We found that mandibular cortical and cancellous bone loss were rescued in FcγRIIb-/- mice administered with etanercept. Etanercept significantly upregulated the expression of osteoblast specific genes including Osx, Alp, and Ocn expression, and downregulated the expression of genes influencing osteoclastogenesis such as TNF-α, Trap, RANKL/OPG ratio in WT. However, Osx, Col1a1, Alp, and Ocn were increased in FcγRIIb-/- mice-treated with etanercept without any change in osteoclast marker genes.
Imbalance between activating and inhibitory FcγR functions disposes individuals to autoimmune inflammatory disease. FcγRIIb inhibition promotes the overproduction of pro-inflammatory cytokines, including TNF-α which is active in inflammatory diseases, including Grave’s disease, rheumatoid arthritis, periodontitis and SLE [28]. In periodontitis, TNF-α was involved in immunoregulatory and inflammatory processes that recruits neutrophils and other leukocytes to the inflammation site. Elevations in TNF-α serum level were found in both SLE mouse models and in lupus patients with periodontitis, and these elevations positively correlated with disease activity [12, 25, 29]. We observed that FcγRIIb-deficient males had dramatically increased serum levels of TNF-α, IFNγ, IL-6, and IL-17A, whereas level of IL-23, IL-1α, IL-12p70, IL-1β, IL-10, IL-27, IFNβ, and GM-CSF remained unchanged. MCP-1 production was slightly increased in FcγRIIb-/- mice. These findings were consistent with clinical investigations in SLE patients, since increased expression of TNF-α, IFNγ, IL-6, and IL-17A had been documented [13, 30, 31]. SLE patients had a worse periodontitis due to high IFNγ levels [2]. Salivary concentrations of IL-6, and IL-17A were increased in SLE patients with periodontitis [31]. Our results showed a similar alteration of proinflammatory cytokines associated with mandibular bone loss in the absence of FcγRIIb.
Cytokines are involved in osteoimmunology and inflammatory bone diseases. An increase in proinflammatory cytokines may contribute to dysregulation of RANKL/OPG cascades resulting in enhanced osteoclastogenesis. Deletion of FcγRIIb increased proinflammatory cytokines, TNF-α, IFNγ, IL-6, and IL-17A, that mediated cancellous and cortical bone loss. Bone destruction is accelerated in inflammatory diseases associated with increased TNF-α production, including ankylosing spondylitis, inflammatory bowel disease, periodontitis and rheumatoid arthritis. TNF-α stimulates bone resorption by acting directly on osteoclast precursors to promote osteoclastogenesis. It also acts on osteoblast to induce RANKL production. High serum levels of TNF-α and IL-6 in patients with SLE have been reported [32]. IL-17A induces bone resorption downstream of TNF-α. IL-17A blockade attenuates TNF-α-mediated inflammatory arthritis and bone loss in transgenic mice [33]. The role of IFNγ in the regulation of bone formation and bone resorption remains controversial. A study of Duque et al, indicated that IFNγ increased cancellous bone volume by increasing osteoblast and osteoclast number in both sham and ovariectomized (OVX) mice [34]. In contrast, IFNγ receptor knockout mice are osteopenic due to decreased bone formation and bone resorption. Mice with silencing of IFNγ receptor signaling are protected from OVX-induced bone loss [35] Others report that while IFNγ has a direct action to inhibit osteoclast formation by osteoclast precursors, it also has indirect actions to stimulate osteoclastogenesis through stimulating RANKL expression and TNF-α secretion from T cell [36].
TNF inhibitor increased serum PTH level in patients with rheumatoid arthritis [18]. Anti-TNF-α therapy in Crohn’s disease, a disorder characterized by overproduction of TNF-α resulted in higher levels of PTH [37]. Our findings are consistent with these studies finding that serum PTH was elevated following etanercept administration. We speculated that the increased bone formation after anti-TNF-α treatment might be driven at least in part by this increase in PTH levels. TNF-α, Trap, RANKL/OPG ratio, makers of bone resorption, were decreased in WT-treated with etanercept, indicating reduced bone resorption. However, we did not observe any change in bone resorption in FcγRIIb-/- mice after anti-TNF-α treatment, possibly due to high serum level of PTH.
Six months old mice lacking FcγRIIb developed SLE and were susceptible to TNF-α-induced inflammatory bone loss in the mandible. Moreover, FcγRIIb-/- mice treated with etanercept were strongly protected from TNF-α-mediated mandibular bone loss. Absence of FcγRIIb increased bone formation and decreased inflammatory cytokines after administration of a TNF-α blocker. Our recent findings suggest that blockade of TNF-α may be beneficial for periodontal diseases in SLE patients.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
Etanercept prevents TNF-α mediated mandibular bone loss in FcγRIIb-/- lupus model
Facebook
Twitter
Linkedin
Whatsapp
